Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

A multi-disciplinary research team from the Universities of Oxford, MRC LMB, Liverpool, Cancer Research UK and pharma (Forma Therapeutics) has performed structural studies of USP7 inhibitor-enzyme interactions, demonstrating that ubiquitin-specific proteases (USPs) are tractable drug targets for cancer and also other diseases.

Professor Benedikt Kessler and Dr Adan Pinto-Fernandez from Oxford’s Target Discovery Institute were part of this study.

Read more